- Home
- BHE vs RCUS Comparison
BHE vs RCUS Comparison
Compare BHE & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHE
- RCUS
- Stock Information
- Founded
- BHE 1979
- RCUS 2015
- Country
- BHE United States
- RCUS United States
- Employees
- BHE N/A
- RCUS N/A
- Industry
- BHE Electrical Products
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- BHE Technology
- RCUS Health Care
- Exchange
- BHE Nasdaq
- RCUS Nasdaq
- Market Cap
- BHE 1.5B
- RCUS 1.2B
- IPO Year
- BHE 1990
- RCUS 2018
- Fundamental
- Price
- BHE $41.12
- RCUS $11.07
- Analyst Decision
- BHE Strong Buy
- RCUS Buy
- Analyst Count
- BHE 3
- RCUS 11
- Target Price
- BHE $43.00
- RCUS $31.11
- AVG Volume (30 Days)
- BHE 285.0K
- RCUS 1.1M
- Earning Date
- BHE 01-29-2025
- RCUS 02-25-2025
- Dividend Yield
- BHE 1.65%
- RCUS N/A
- EPS Growth
- BHE N/A
- RCUS N/A
- EPS
- BHE 1.72
- RCUS N/A
- Revenue
- BHE $2,656,105,000.00
- RCUS $263,000,000.00
- Revenue This Year
- BHE $4.55
- RCUS $127.65
- Revenue Next Year
- BHE $7.17
- RCUS N/A
- P/E Ratio
- BHE $23.91
- RCUS N/A
- Revenue Growth
- BHE N/A
- RCUS 119.17
- 52 Week Low
- BHE $27.44
- RCUS $10.63
- 52 Week High
- BHE $52.57
- RCUS $20.31
- Technical
- Relative Strength Index (RSI)
- BHE 35.31
- RCUS 34.34
- Support Level
- BHE $40.80
- RCUS $10.63
- Resistance Level
- BHE $42.96
- RCUS $13.49
- Average True Range (ATR)
- BHE 1.07
- RCUS 0.77
- MACD
- BHE 0.08
- RCUS -0.13
- Stochastic Oscillator
- BHE 14.81
- RCUS 13.88
About BHE Benchmark Electronics Inc.
Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and advanced manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia and Europe of which key revenue is derived from the Americas.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.